News ArchivesRead News

Your Weekly Parkinson's News Update for the Week of 12.17.18

Monday December 17, 2018
New Art Initiative Aims to Improve Understanding
and Discussion of Parkinson’s Off Periods
Parkinson's News Today
"A new initiative by Acorda Therapeutics uses art to help people with Parkinson’s recognize and communicate about their off-period experiences.
The initiative, called Framing OFF Through Art, builds on Acorda’s Live Well. Do Tell program, launched earlier this year.
Framing OFF Through Art includes artwork inspired by the experiences of patients with Parkinson’s and their caregivers. The artists who created the pieces also have personal connections to the disease. Each artist partnered with two patients and their caregivers. The art aims to educate and encourage others with Parkinson’s and their care partners to identify off-period symptoms and discuss them with their healthcare professionals."
Chinese Medicinal Formula Shows Success
in Models of Parkinson’s
Hindawi Journal
Today, the idea that Parkinson’s might arise from the intestine, not the brain, “is one of the most exciting things in Parkinson’s disease,” says Heinz Reichmann, a neurologist at the University of Dresden in Germany. Additionally, researchers speculate that some sort of pathogen, perhaps a virus, might travel along the body’s nervous system, leaving a trail of Lewy bodies.
"There is no shortage of passageways: The intestine contains so many nerves that it’s sometimes called the body’s second brain. And the vagus nerve offers a direct connection between those nerves in the gut and the brain."
Novel Cellular Model of Human Microglia to Enable Neurodegenerative Disease Drug Discovery and Development
Select Science
Microglia are commonly described as the brain's immune cells. They offer scientists the opportunity to integrate this clinically important cell type into their in vitro models and assays of neurogenesis and neurodegeneration. The biosciences company Axol now generates physiologically relevant Human iPSC-derived Microglia from a single donor with a normal karyotype, providing a homogenous population that is assay-ready in just four days.